Tucidinostat

An HDAC inhibitor

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥600.00

480.00

- +
10mg

￥937.00

750.00

- +
25mg

￥1687.00

1350.00

- +
50mg

￥2712.00

2170.00

- +
100mg

￥4275.00

3420.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Chidamide is an inhibitor of histone deacetylases (HDACs; IC₅₀s = 0.095, 0.160, 0.067, 0.733, 0.078, and 0.432 ?M for HDAC1-3, 8, 10, and 11, respectively).¹ It is selective for these HDACs over HDAC4-7 and 9 (IC₅₀s = >30 ?M for all). Chidamide also inhibits nicotinamide phosphoribosyltransferase (Nampt; IC₅₀ = 2.1 ?M).² It inhibits cell growth in a panel of 18 cancer cell lines (GI₅₀s = 0.4-40 ?M) but has no effect on the growth of non-cancerous CCC-HEK human fetal kidney or CCC-HEL human liver cells (GI₅₀s = >100 ?M).¹ In vivo, tucidinostat (12.5, 25, and 50 mg/kg) reduces tumor growth in HCT-8, A549, BEL-7402, and MCF-7 mouse xenograft models.¹

1.Ning, Z.-Q., Li, Z.-B., Newman, M.J., et al.Chidamide (CS055/HBI-8000): A new histone deacetylase inhibitor of the benzamide class with antitumor activity and the ability to enhance immune cell-mediated tumor cell cytotoxicityCancer Chemother. Pharmacol.69(4)901-909(2012) 2.Wu, Y., Wang, L., Huang, Y., et al.Nicotinamide phosphoribosyltransferase (NAMPT) is a new target of antitumor agent chidamideACS Med. Chem. Lett.11(1)40-44(2020)